BetterLife Pharma (BETRF) Total Debt (2011 - 2026)

BetterLife Pharma has reported Total Debt for 16 years, with the latest figure at $1.3 million in Q2 2026.

• On a quarterly basis, Total Debt rose 6.84% year-over-year to $1.3 million in Q2 2026; TTM through Apr 2026 was $1.3 million, a 6.84% increase from a year earlier, with the FY2026 full-year figure at $1.3 million, down 25.21% from the prior year.
• Total Debt was $1.3 million for Q2 2026 at BetterLife Pharma, down from $1.3 million in the prior quarter.
• The five-year high for Total Debt was $1.7 million in Q1 2025, with the low at $289275.6 in Q2 2022.
• Average Total Debt over 5 years is $881904.9, with a median of $913732.3 recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Debt sank 44.38% in 2022, then soared 86.59% in 2024.
• Over 5 years, Total Debt stood at $584189.6 in 2022, then surged by 31.22% to $766544.5 in 2023, then advanced by 20.49% to $923627.7 in 2024, then decreased by 1.07% to $913732.3 in 2025, then jumped by 38.69% to $1.3 million in 2026.
• The last three Total Debt figures came in at $1.3 million (Q2 2026), $1.3 million (Q1 2026), and $913732.3 (Q3 2025), per Business Quant data.